Abstract
Fibroblast growth factor 21 (FGF21) is emerging as a key regulator of energy homeostasis and presents a novel target for the development of therapies for the treatment of diabetes, cardiovascular disease and obesity. Recent publications have demonstrated that FGF21 resides downstream of a complex network of transcriptional regulators which modulate its expression in response to a wide array of physiological stimuli or pharmacologic agents. The manner in which these mechanisms are integrated to regulate FGF21 transcription, production and subsequent secretion is poorly understood. While FGF21 is detected in many metabolically active tissues and is regulated by several of the known transcription factors involved in metabolic control little is known about how these pathways are integrated. In this review, we discuss the data presented to date on regulation of FGF21 by a wide array of transcription factors and explore how it relates to metabolic regulation in vivo.
Keywords: FGF21, metabolism, expression regulation, homeostasis, transcription, metabolic, stimuli, metabolic regulation, obesity, pharmacologic agents
Current Diabetes Reviews
Title:FGF21: The Center of a Transcriptional Nexus in Metabolic Regulation
Volume: 8 Issue: 4
Author(s): A. C. Adams and A. Kharitonenkov
Affiliation:
Keywords: FGF21, metabolism, expression regulation, homeostasis, transcription, metabolic, stimuli, metabolic regulation, obesity, pharmacologic agents
Abstract: Fibroblast growth factor 21 (FGF21) is emerging as a key regulator of energy homeostasis and presents a novel target for the development of therapies for the treatment of diabetes, cardiovascular disease and obesity. Recent publications have demonstrated that FGF21 resides downstream of a complex network of transcriptional regulators which modulate its expression in response to a wide array of physiological stimuli or pharmacologic agents. The manner in which these mechanisms are integrated to regulate FGF21 transcription, production and subsequent secretion is poorly understood. While FGF21 is detected in many metabolically active tissues and is regulated by several of the known transcription factors involved in metabolic control little is known about how these pathways are integrated. In this review, we discuss the data presented to date on regulation of FGF21 by a wide array of transcription factors and explore how it relates to metabolic regulation in vivo.
Export Options
About this article
Cite this article as:
C. Adams A. and Kharitonenkov A., FGF21: The Center of a Transcriptional Nexus in Metabolic Regulation, Current Diabetes Reviews 2012; 8(4) . https://dx.doi.org/10.2174/157339912800840505
DOI https://dx.doi.org/10.2174/157339912800840505 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Methadone and the Heart: What the Clinician Needs to Know
Current Drug Abuse Reviews Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology Progress and Prospects of Stem Cells in Treatment of Drug Resistant Tuberculosis
Current Respiratory Medicine Reviews Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A Randomized, Double Blind, Controlled, Dose Dependent Clinical Trial to Evaluate the Efficacy of a Proanthocyanidin Standardized Whole Cranberry (Vaccinium macrocarpon) Powder on Infections of the Urinary Tract
Current Bioactive Compounds Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations
Infectious Disorders - Drug Targets Cell-based Treatment of Cerebral Palsy: Still a Long Way Ahead
Current Stem Cell Research & Therapy Impacts of Nanoparticles on Cardiovascular Diseases: Modulating Metabolism and Function of Endothelial Cells
Current Drug Metabolism Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support
Current Immunology Reviews (Discontinued) The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?
CNS & Neurological Disorders - Drug Targets Molecularly Imprinted Sol-Gel Materials for Medical Applications
Current Topics in Medicinal Chemistry Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued) A Valuable Animal Model of Spinal Cord Injury to Study Motor Dysfunctions, Comorbid Conditions, and Aging Associated Diseases
Current Pharmaceutical Design